Percutaneous coronary interventions and statins therapy

Therapeutic Advances in Cardiovascular Disease

Volumn 2, Issue 2, 2008, Pages 101-107

  Nusca, Annunziata ^a   Melfi, Rosetta ^a   Sciascio, Germano ^a  

^a NONE   (Italy)

Author keywords

Angioplasty; Pharmacology; Stents

Indexed keywords

ATORVASTATIN; CONTRAST MEDIUM; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; PLACEBO;

ANGIOCARDIOGRAPHY; ANGIOPLASTY; ATHEROSCLEROTIC PLAQUE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTRAST MEDIUM INDUCED NEPHROPATHY; CORONARY ARTERY DISEASE; DRUG MEGADOSE; ENDOTHELIUM; HEART INFARCTION; HEART MUSCLE INJURY; HUMAN; INFLAMMATION; LOADING DRUG DOSE; NEPHROTOXICITY; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SECONDARY PREVENTION; STABLE ANGINA PECTORIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COMBINED MODALITY THERAPY; CORONARY ARTERY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; STENTS;

EID: 68749093258     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944708089983     Document Type: Review

References (38)

1. Abdelmeguid, A.E., Topol, E.J., Whitlow, P.L., Sapp, S.K. and Ellis, S.G. (1996) Significance of mild transient release of creatine-kinase MB fraction after percutaneous coronary interventions. Circulation 94: 1528-1536.
2. Bellosta, S., Via, D., Canavesi, M., Pfister, P., Fumagalli, R., Paoletti, R. et al. (1998) HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18: 1671-1678.
3. Bonetti, P.O., Lerman, L.O., Napoli, C. and Lerman, A. (2003) Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J 24: 225-248.
4. Brener, S.J., Ellis, S.G., Schneider, J., Topol, E.J. (2002) Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J 23: 869-876.
5. Briel, M., Schwartz, G.G., Thompson, P.L., de Lemos, J.A., Blazing, M.A., van Es, G.A. et al. (2006) Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA 295: 2046-2056.
6. Chan, A.W., Bhatt, D.L., Chew, D.P., Quinn, M.J., Moliterno, D.J., Topol, E.J. et al. (2002) Early and sustained survival benefit associated with statin therapy. Circulation 105: 691-696.
7. Chan, A.W., Chew, D.P., Bhatt, D.L., Moliterno, D.J., Topol, E.J., Ellis, S.G. et al. (2004) Relation of inflammation and benefit of statins after percutaneous intervention on frequency of periprocedural myocardial injury. Am J Cardiol 94: 1363-1366.
8. Chang, S.M., Yazbek, N. and Lakkis, N.M. (2004) Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc Interv 62: 193-197.
9. Davignon, J. (2004) Beneficial cardiovascular pleiotropic effects of statins. Circulation 109: 39-43.
10. Desmet, W., Dens. J., Coussement, P. and van de Werf, F. (2002) Does adenosine prevent myocardial micronecrosis following percutaneous coronary intervention? The ADELINE pilot trial. Heart 88: 293-295.
11. Gruberg, L., Mintz, G.S., Mehran, R., Gangas, G., Lansky, A.J., Kent, K.M. et al. (2000) The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. JACC 36: 1542-1548.
12. Hernández-Perera, O., Pérez-Sala, D., Navarro-Antolín, J., Sánchez-Pascuala, R., Hernández, G., Díaz, C. et al. (1998) Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101: 2711-2719.
13. Herrmann, J., Lerman, A., Baumgart, D., Volbracht, L., Schulz, R., von Birgelen, C. et al. (2002) Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 106: 2180-2183.
14. Hinoi, T., Matsuo, S., Tadehara, F., Tsujiyama, S. and Yamakido, M. (2005) Acute effect of atorvastatin on coronary circulation measured by transthoracic
15. Doppler echocardiography in patients without coronary artery disease by angiography. Am J Cardiol 96: 89-91.
16. Ichiki, T., Takeda, K., Tokunou, T., Iino, N., Egashira, K., Shimokawa, H. et al. (2001) Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 21: 1896-1901.
17. Ioannidis, J.P.A., Karvouni, E. and Katritis, D.G. (2003) Mortality risk conferred by small elevations of creatinine kinase-MB isoenzyme after percutaneous intervention. J Am Coll Cardiol 42: 1406-1411.
18. Khanal, S., Attallah, N., Smith, D.E., Kline-Rogers, E., Share, D., O'Donnell, M.J. et al. (2005) Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Medicine 118: 843-849.
19. Kinlay, S., Schwartz, G.G., Olsson, A.G., Rifai, N., Leslie, S.J., Sasiela, W.J. et al. (2003) Myocardial ischemia reduction with aggressive cholesterol lowering study investigators. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 108: 1560-1566.
20. Kurz, D.J., Naegeli, B. and Bertel, O. (2000) A double-blind, randomized study of the effect of immediate intravenous nitroglycerin on the incidence of post-procedural chest pain and minor myocardial necrosis after elective coronary stenting. Am Heart J. 139: 35-43.
21. Lindsay, J., Apple, S., Pinnow, E.E., Gevorkian, N., Gruberg, L., Satler, L.F. et al. (2003) Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatine. Cathet Cardiovasc Intervent 59: 338-343.
22. Long-term Intervention with Paravstatin in Ischaemic Disease (LIPID) study group. (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339: 1349-1357.
23. Morikawa, S., Takabe, W., Mataki, C., Kanke, T., Itoh, T., Wada, Y. et al. (2002) The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 9: 178-183.
24. Murphy, S.W., Barrett, B.J. and Parfrey, P.S. (2000) Contrast nephropathy. J Am Soc Nephrol 11: 177-182.
25. Pasceri, V., Patti, G., Nusca, A., Pristipino, C., Richichi, G., Di Sciascio, G. et al. (2004) ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 110: 674-678.
26. Patti, G., Chello, M., Pasceri, V., Colonna, D., Nusca, A., Miglionico, M. et al. (2006) Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol 48: 1560-1566.
27. Patti, G., Nusca, A., Chello, M., Pasceri, V., D'Ambrosio, A., Vetrovec, G.W. et al. (2008) Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol 101: 279-285.
28. Patti, G., Pasceri, V., Colonna, G., Miglionico, M., Fischetti, D., Sardella, G. et al. (2007) Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 49: 1272-1278.
29. Rihal, C.S., Textor, S.C., Grill, D.E., Berger, P.B., Ting, H.H., Best, P.J. et al. (2002) Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105: 2259-2264.
30. Sacks, F.M., Pfeffer, M.A., Moye, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G. et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: cholesterol and recurrent events trial investigators. N Engl J Med 335: 1001-1009.
31. Sanguigni, V., Pignatelli, P., Lenti, L., Ferro, D., Bellia, A., Carnevale, R. et al. (2005) Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 111: 412-419.
32. Scandinavian Simvastatin Survival Study (4S). ( 1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 344: 1383-1389.
33. Schwartz, G.G., Olsson, A.G., Ezekowitz, M.D., Ganz, P., Oliver, M.F. Waters, D. et al. (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA 285: 1711-1718.
34. The EPISTENT Investigators. (1998) Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 352: 87-92.
35. Turer, A.T., Mahaffey, K.W., Gallup, D., Weaver, W.D., Christenson, R.H., Every, N.R. et al. (2005) Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction. Curr Control Trials, Cardiovasc Med 6: 12-15.
36. Wang, F.W., Osman, A., Otero, J., Stouffer, G.A., Waxman, S., Afzal, A. et al. (2003) Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker. Circulation 107: 2914-2919.
37. Wassmann, S., Faul, A., Hennen, B., Scheller, B., Böhm, M., Nickenig, G. et al. (2003) Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res 93: e98-103.
38. Xenos, E.S., Stevens, S.L., Freeman, M.B., Cassada, D.C. and Goldman, M.H. (2005) Nitric oxide mediates the effect of fluvastatin on intercellular adhesion molecule-1 and platelet endothelial cell adhesion molecule-1 expression on human endothelial cells. Ann Vasc Surg 19: 386-392.